Abstract: Monofunctional polyfluorooxetane oligomers and polymers are prepared by the cationic polymerization of fluorooxetane monomers with a monoalcohol. The fluorooxetane oligomers or polymers can be copolymerized with generally cyclic ethers. Alternatively, the polyfluorooxetane oligomer or polymer having a single hydroxyl end group can be functionalized with a variety of compounds so as to yield a functional end group such as an acrylate, a methacrylate, an allylic, an amine, etc., with the functionalized oligomer or polymer being suitable for use in radiation curable or thermal curable coating compositions. These functionalized polymers can be copolymerized and cured to provide improvements in wetting and surface properties that have previously been provided by migratory chemicals such as waxes and oils.

Abstract: Disclosed are liquid crystalline compounds which (i) are characterized in that the compounds have a wide temperature range in which the compounds exhibit a liquid crystal phase, are low in viscosity, and have a negative and large &Dgr;&egr;, (ii) are readily mixed with other various liquid crystal materials even at low temperatures, and (iii) are useful as component of liquid crystal compositions suitable both for TFT type display mode and IPS mode; and liquid crystal composition comprising the liquid crystalline compound; the compounds are expressed by the general formula (1) wherein R1 represents an alkyl group having 1 to 15 carbon atoms; ring A1, ring A2, and ring A3 independently represent trans-1,4-cyclohexylene group, trans-1,4-silacyclohexylene group, pyrimidine-2,5-diyl group, pyridine-2,5-diyl group, 1,3-dioxane-2,5-diyl group, tetrahydropyran-2,5-diyl group, 1,3-dithian-2,5-diyl group, or tetrahydrothiopyran-2,5-diyl group, or 1,4-phenylene group in which one or more hydrogen atom

Abstract: Monofunctional polyfluorooxetane oligomers and polymers are prepared by the cationic polymerization of fluorooxetane monomers with a monoalcohol. The fluorooxetane oligomers or polymers can be copolymerized with generally cyclic ethers. Alternatively, the polyfluorooxetane oligomer or polymer having a single hydroxyl end group can be functionalized with a variety of compounds so as to yield a functional end group such as an acrylate, a methacrylate, an allylic, an amine, etc., with the functionalized oligomer or polymer being suitable for use in radiation curable or thermal curable coating compositions. These functionalized polymers can be copolymerized and cured to provide improvements in wetting and surface properties that have previously been provided by migratory chemicals such as waxes and oils.

Abstract: A novel pyrylium compound is represented by the general formula (I): wherein X is oxygen or sulfur, Y− is a monovalent anion, n is an integer of 2 or 3, and M is hydrogen or an alkali metal. This pyrylium compound functions as a labeling agent by intermolecular bonding to nucleic acids, and as a fluorescence label having a chemical bond with the nucleic acids and an excitation wavelength in a visible light region.

Abstract: Photochromic spirofluorenopyran compounds corresponding to the general formula (I): in which B, B′, R1 to R4 and G have the meanings defined herein. The compounds of the invention are useful in the production of photochromic articles, particularly articles made of synthetic resin materials, and exhibit rapid darkening and brightening rates, as well as long useful service lives. By appropriate selection of substituents, it is possible to adjust the properties of the compounds such as absorption maxima (color), brightening rate, etc.

Abstract: Photochromic spirofluorenopyran compounds corresponding to the general formula (I): in which B, B′, R1 to R4 and G have the meanings defined herein. The compounds of the invention are useful in the production of photochromic articles, particularly articles made of synthetic resin materials, and exhibit rapid darkening and brightening rates, as well as long useful service lives. By appropriate selection of substituents, it is possible to adjust the properties of the compounds such as absorption maxima (color), brightening rate, etc.

Abstract: The present invention provides a liquid crystal compound having a negative dielectric constant anisotropy value of a large absolute value, a controlled optically anisotropy value, a high resistivity, a high voltage retention, and high stability against heat and ultraviolet radiation; a liquid crystal composition containing such a liquid crystal compound; and a liquid crystal display element fabricated from such a liquid crystal composition.There is disclosed a liquid crystal compound having 6,6-difluorotetrahydropyran-2,5-diyl, 6,6-difluoro-2,3-dihydro-6H-pyran-2,5-diyl, and/or 6-fluoro-3,4-dihydro-2H-pyran-2,5-diyl in the skeleton thereof; a liquid crystal composition containing such a liquid crystal compound; and a liquid crystal display element fabricated from such a liquid crystal composition.

Abstract: Novel cyclic ether vitamin D3 compounds having a cyclic ether side chain are disclosed. These compounds were first identified as metabolites of 3-epi vitamin D3 produced via a tissue-specific metabolic pathway which catalyzes the formation of a cyclic ether structure. Also disclosed are 1.alpha.(OH) 3-epi vitamin D3 compounds, which are produced via the epimerization of a 3-.beta.-hydroxyl group of 1.alpha.(OH) vitamin D3 precursor in vivo. The vitamin D3 compounds of the present invention can be used as substitutes for natural and synthetic vitamin D3 compounds.

Abstract: The present invention relates to a process for the production of cyanine dyes with their methine chain showing group (M) and the charge compensation occuring by linked end groups through transformation of cationic cyanine dyes comprising group (D) with CH-acid compounds of the following formula (I) B.sub.1 --CH.sub.2 --B.sub.2 in an inert solvent, the substituents having the significance given in the description.

Abstract: Triene-containing compounds which mimic the chemical and/or biological activity of the spongistatins are provided, as are methods and intermediates useful in their preparation.

Abstract: The substituted 4H-pyrans are prepared by reacting either aldehydes or ylidene compounds with suitably substituted .beta.-diketones. The substituted 4H-pyrans according to the invention are suitable as active compounds in medicaments, in particular for the treatment of disorders of the central nervous system.

Abstract: This invention pertains to a method for liquid phase fluorination for perfluorination of a wide variety of hydrogen-containing compounds.

Abstract: The present invention relates to novel 3,3-(disubstituted)cyclohexan-1-ol dimers and related compounds, pharmaceutical compositions containing these compounds, and their use in treating allergic and inflammatory diseases and for inhibiting the production of Tumor Necrosis Factor (TNF).

Abstract: This invention pertains to a method for liquid-phase fluorination for perfluorination of a wide variety of hydrogen-containing compounds.

Abstract: A process for the preparation of a perfluoropolyether having a general formula: ##STR1## as defined hereinbefore, which process includes the direct fluorination with elemental fluorine of a polyether having a general formula: ##STR2## as defined hereinbefore, wherein the fluorination is carried out in the presence of a solvent which is an ether having at least one substituent R.sub.F, wherein R.sub.F is a fluorinated hydrocarbon group. The said solvent ether is preferably a fluorinated volatile ether. The said solvent ether preferably has at least two groups R.sub.F which may be the same or different groups. Each group R.sub.F preferably has from two to four carbon atoms and at least two fluorine atoms. The said solvent ether may be an alicyclic ether having from 3 to 5 carbon atoms in its alicyclic ring.

Abstract: This invention pertains to perfluoropolyethers and perhalogenated chlorofluoropolyethers that can be prepared by fluorinating addition polymers made by polymerizing epoxides.

Abstract: This invention pertains to a method for liquid phase fluorination for perfluorination of a wide variety of hydrogen-containing compounds.

Abstract: A process for the preparation of a brominated compound which comprises the step of reacting at least one compound selected from the group consisting of a chloroformate, a chlorosulfite and a chlorophosphite with a brominating agent for a time sufficient to obtain at least one brominated compound. In particular, an alcohol is converted into a chloroformate, chlorosulfite or a chlorophosphite, which is then brominated to obtain the desired product. In another embodiment, a brominating agent is reacted with a reactant selected from the group consisting of thionyl chloride, phosgene and phosphorous oxychloride, followed by contacting the reaction product obtained with an alcohol to be brominated.

Abstract: This invention pertains to a method for liquid phase fluorination for perfluorination of a wide variety of hydrogen-containing compounds.

Abstract: This invention pertains to a method for liquid phase fluorination for perfluorination of a wide variety of hydrogen-containing compounds.

Abstract: This invention pertains to a method for liquid phase fluorination for perfluorination of a wide variety of hydrogen-containing compounds.

Abstract: Compounds having the formula I: ##STR1## are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis and allograft rejection and in preventing the formation of atherosclerotic plaques.

Abstract: The invention concerns a cyclic ether derivative of the formula I ##STR1## wherein Ar.sup.1 is optionally substituted phenyl, naphthyl or a 9- or 10-membered bicyclic heterocyclic moiety;A.sup.1 is a direct link to X.sup.1 or (1-3C)alkylene;X.sup.1 is oxy, thio, sulphinyl, sulphonyl or imino;Ar.sup.2 is optionally substituted phenylene or pyridylene;R.sup.1 includes hydrogen, (1-4C)alkyl, (1-4C)alkcxycarbonyl and (1-4C)alkylthio; andR.sup.2 and R.sup.3 together form a group of the formula --A.sup.2 --X.sup.2 --A.sup.3 -- which, together with the carbon atom to which A.sup.2 and A.sup.3 are attached, defines a ring having 5 to 7 ring atoms, wherein each of A.sup.2 and A.sup.3 is (1-3C)alkylene and X.sup.2 is oxy, thio, sulphinyl or sulphonyl;or a pharmaceutically-acceptable salt thereof.The compounds of the invention are inhibitors of the enzyme 5-lipoxygenase.

Abstract: A process for the preparation of a brominated compound which comprises the step of reacting at least one compound selected from the group consisting of a chloroformate, a chlorosulfite and a chlorophosphite with a brominating agent for a time sufficient to obtain at least one brominated compound. In particular, an alcohol is converted into a chloroformate, chlorosulfite or a chlorophosphite, which is then brominated to obtain the desired product. In another embodiment, a brominating agent is reacted with a reactant selected from the group consisting of thionyl chloride, phosgene and phosphorous oxychloride, followed by contacting the reaction product obtained with an alcohol to be brominated.

Abstract: This invention pertains to a method for liquid phase fluorination for perfluorination of a wide variety of hydrogen-containing compounds.

Abstract: A process for fluorinating hydrogenated ethereal compounds by direct reaction with elemental F.sub.2 diluted with an inert gas, wherein the starting compound is in the liquid phase, said fluorination being carried out in the presence of a per fluoropolyetheral compound and of an alkaline metal fluoride.

Abstract: Compounds suitable for being used as lubricants, having general formula:(I) RO--(C.sub.3 F.sub.6 O).sub.m --(CFXO).sub.n --CFX--L, or(II) R"CFXO--(C.sub.3 F.sub.6 O).sub.x (CFXO).sub.y --(C.sub.2 F.sub.4 O).sub.z --CFX--L, whereR=--CF.sub.3, --C.sub.2 F.sub.5, --C.sub.3 F.sub.7X=F, --CF.sub.3R"=F, --CF.sub.3, --C.sub.2 F.sub.5m=an integer from 3 to 100n=a finite integer, or =zero, wherefore m+n ranges from 3 to 100, provided that, if n is finite, m/n ranges from 5 to 20 and R is preferably =CF.sub.3, if n=zero, R is preferably --C.sub.2 F.sub.5 or --C.sub.3 F.sub.7x=a finite integer, or =zeroy, z=finite integers, such that x+y+z ranges from 5 to 200, while (x+z)/y ranges from 5 to 0.5, provided that when x=zero, z/y ranges from 1 to 0.5 and y+z ranges from 5 to 200 n while X is preferably F, and R"=LL=group Y-Z, where:Y=--CH.sub.2 O--, --CH.sub.2 --OCH.sub.2, --CF.sub.2, --CF.sub.

Abstract: 3,4-dihydro-2H-pyrans I ##STR1## where R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are each H or C.sub.1 -C.sub.6 -alkyl and R.sup.3 is not C.sub.2 -C.sub.4 -alkyl when A is COOR.sup.5 and A is COOR.sup.5, .dbd.CHOR.sup.5, in which R.sup.5 is C.sub.1 -C.sub.4 -alkyl, or CH.sub.2 OR.sup.6, in which R.sup.6 is C.sub.1 -C.sub.4 -alkyl or is benzyl which is unsubstituted or substituted by C.sub.1 -C.sub.4 -alkyl, alkoxy or halogen, or is formyl, C.sub.2 -C.sub.4 -alkylcarbonyl or benzoyl which is unsubstituted or substituted by C.sub.1 -C.sub.4 -alkyl, alkoxy or halogen, are prepared by eliminating an alcohol from a 2-alkoxytetrahydropyran II ##STR2## where R.sup.7 is C.sub.1 -C.sub.18 -alkyl and A' is COOR.sup.5, CH(OR.sup.5).sub.2 or CH.sub.2 OR.sup.6, in which R.sup.5 and R.sup.

Abstract: New tetrahydropyran derivatives of the formula I ##STR1## in which G is H.sub.2 or .dbd.O, R.sup.1 and R.sup.2 are each an alkyl group having 1-10 C atoms, it also being possible for one or two CH.sub.2 groups to be replaced by O atoms, or are F, Cl, Br or CN, R.sup.2 is also H, A.sup.1 and A.sup.2 are each 1,4-phenylene, 1,4-cyclohexylene, 1,3-dioxane-2,5-diyl, piperidine-1,4-diyl, 1,4-bicyclo[2.2.2]octylene or pyrimidine-2,5-diyl groups which are unsubstituted or substituted by 1-4 F atoms, Z.sup.1 and Z.sup.2 are each --CO--O--, --O--CO--, --CH.sub.2 CH.sub.2 --, --OCH.sub.2 --, --CH.sub.2 O--, or a single bond, m and n are each 0, 1, 2 or 3, but (m+n) is at least 1 and at most 3, it being possible, when m is 2 or 3, for the group A.sup.1 and, when n is 2 or 3, for the groups A.sup.2 each to be identical or different from one another, and the acid addition salts of those among these compounds which are basic, are suitable for use as components in liquid-crystal dielectrics.

Abstract: Fluorinated ether, process for their preparation, and use of the fluorinated ethers as inert fluids.

Abstract: Ring opened halogenated Resorcyclic Acid Lactone (RAL) derivatives having the structure: ##STR1## are used to increase rumen fermentation efficiency.

Abstract: A process for selectively preparing isomers of polysubstituted pyrylium salts from isoolefins or isoolefin precursors comprises diacylating the isoolefin or isoolefin precursor with a carboxylic acid anhydride in the presence of an acid having a Hammett acidity function, at about 22.degree.-25.degree. C. when pure, between -10 and -5. This method is selective to obtain the most substituted isomer of pyrylium salt that can be obtained from the isoolefin or isoolefin precursor.